Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients

BackgroundAlthough serum lipoprotein(a) [Lp(a)J is an independent risk factor for atherosclerosis in the general population and Lp(a) levels are increased in hemodialysis patients, an association of Lp(a) with the risk of clinical events attributed to atherosclerosis has not been established in the chronic hemodialysis patient population. We therefore determined the association between Lp(a) levels and the risk of clinical events of presumed atherosclerotic etiology in a prospective study of an outpatient hemodialysis population. Methods and ResultsLp(a) was measured by radioimmunoassay in a baseline cardiovascular disease risk assessment in a consecutive series of 129 hemodialysis patients. The relation between baseline Lp(a) and clinical events of presumed atherosclerotic etiology was determined during 48 months of follow-up. Hemodialysis patients had a median Lp(a) concentration that was approximately four times as high as the median Lp(a) concentration in normal controls and twice as high as the levels in controls with angiographic evidence of coronary artery disease [median Lp(a), 38.4 versus 16.9 mg/dl; p < 0.001]. Baseline Lp(a) levels were no different in participants with or with no history of a previous clinical event at the time of the baseline examination. However, baseline Lp(a) concentration (p < 0.001) and a history of atherosclerotic clinical events (p = 0.001) were associated with clinical events during the period of follow-up. In contrast, baseline serum total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, age, gender, race, or duration of hemodialysis were unrelated to this risk in the prospective study. Stepwise multiple logistic regression analysis demonstrated that serum Lp(a) concentration (p = 0.001) and the presence of a previous clinical event (p = 0.004) were the only independent contributors to the risk of a clinical event during the period of follow-up. ConclusionsLp(a) is an independent risk factor for clinical events attributed to atherosclerotic cardiovascular disease in patients receiving chronic hemodialysis treatment of end-stage renal disease.

[1]  H. Hoff,et al.  Quantification of apo[a] and apoB in human atherosclerotic lesions. , 1991, Journal of lipid research.

[2]  J. Loscalzo,et al.  Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.

[3]  S. Grundy.  Management of hyperlipidemia of kidney disease. , 1990, Kidney international.

[4]  M. Dietel,et al.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.

[5]  M. Debakey,et al.  Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. , 1989, Arteriosclerosis.

[6]  G. Beck,et al.  Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. , 1988, Circulation.

[7]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.

[8]  W. Kohr,et al.  Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Fruchart,et al.  Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. , 1987, Clinical chemistry.

[10]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[11]  H. Naito,et al.  Measurement of total HDL, HDL2 and HDL3 by dextran sulfate-MgCl2 precipitation technique in human serum. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[12]  M. Kameyama,et al.  Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. , 1986, Atherosclerosis.

[13]  H. Naito.  The Association of Serum Lipids, Lipoproteins, and Apolipoproteins with Coronary Artery Disease Assessed by Coronary Arteriography , 1985, Annals of the New York Academy of Sciences.

[14]  A. Gotto,et al.  Relationship of Plasma Lipoprotein Lp(a) Levels to Race and to Apolipoprotein B , 1985, Arteriosclerosis.

[15]  A. Goldberg,et al.  Racial differences in plasma high-density lipoproteins in patients receiving hemodialysis. A possible mechanism for accelerated atherosclerosis in white men. , 1983, The New England journal of medicine.

[16]  D R Jacobs,et al.  Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. , 1982, American journal of epidemiology.

[17]  S. Rostand,et al.  Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. , 1982, Kidney international.

[18]  J. Swets,et al.  Assessment of diagnostic technologies. , 1979, Science.

[19]  W. Hazzard,et al.  Radioimmunoassay of human plasma Lp(a) lipoprotein. , 1977, Journal of lipid research.

[20]  K. Walton,et al.  A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. , 1974, Atherosclerosis.

[21]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[22]  D. Bilheimer,et al.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. , 1972, Biochimica et biophysica acta.

[23]  M. Sentí,et al.  [Lipoprotein(a) and the cardiovascular risk]. , 1994, Revista espanola de cardiologia.

[24]  G. Vanhoutte,et al.  Lipoprotein abnormalities in chronic haemodialysis patients. , 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[26]  P. Fishman,et al.  Platelet X-ray microanalysis in patients with chronic renal failure. , 1985, Acta haematologica.

[27]  A. Goldberg,et al.  Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure. , 1985, Metabolism: clinical and experimental.